Skip to content


#FutureFresenius is transforming our Group and positioning it for the decades ahead. Read more about #FutureFresenius in the story.

Read story

Letter to our shareholders

Fresenius set the strategic course and is moving towards #FutureFresenius with a simplified structure, sharper focus and acceleration of performance.

Read more

Financial Highlights FY/22

Despite a difficult macroeconomic environment, Fresenius met its FY 2022 revised Group sales and earnings targets.

To Group financial figures


37,520 m

+4 %1

FY/21: €37,520 m

Net interest2

-504 m


FY/21: € -504 m


4,252 m


FY/21: €4,252 m



Dec. 31, 2021: 316,078

Net income2,3

1.867 m


FY/21: €1,867 m

Earnings per share2



FY/21: €3,35

1 In constant currency

2 Before special items

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

Management Report

Fresenius is at the heart of healthcare. The focus here is on our services for patients, our clinical decisions, our drugs, our medical devices and technologies – and, above all, our patient care. Every day, our employees improve the quality of life for millions of people around the world.

To the management report